NewsFeed
Headlines ASRM ESHRE FIGO ACOG Fertility and Sterility PCOS
September, 2026
September 2026
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
282930  
Heghine Khachatryan: What Should We Test from a Hematology Perspective?
Heghine Khachatryan/LinkedIn
Jun 12, 2026, 14:01

Heghine Khachatryan: What Should We Test from a Hematology Perspective?

Heghine Khachatryan, Editor in Chief Hemostasis Today, shared a post on LinkedIn:

“Young Cryptogenic Stroke: What Should We Test from a Hematology Perspective?

The SECRETO study demonstrated that thrombophilia abnormalities are relatively common in young patients with cryptogenic ischemic stroke; however, truly high-risk and persistent abnormalities are uncommon. These findings support a targeted and clinically driven approach to hematologic evaluation.

Potential hematologic contributors to young cryptogenic stroke include inherited thrombophilia, antiphospholipid syndrome, hyperhomocysteinemia, myeloproliferative neoplasms, paroxysmal nocturnal hemoglobinuria, cancer-associated hypercoagulability, clonal hematopoiesis, elevated factor VIII, hemolysis-associated thrombosis, platelet disorders, and rare fibrinolytic abnormalities.

A reasonable hematologic evaluation in selected patients may include:

  • Antiphospholipid antibodies (lupus anticoagulant, anticardiolipin antibodies, anti-β2 glycoprotein I antibodies)
  • Inherited thrombophilia testing (Factor V Leiden, Prothrombin G20210A, antithrombin, protein C, protein S)
  • Homocysteine, vitamin B12, and folate
  • Complete blood count, peripheral blood smear, reticulocytes, LDH, bilirubin, and haptoglobin
  • JAK2 V617F, CALR, and MPL mutation analysis when myeloproliferative neoplasms are suspected
  • High-sensitivity flow cytometry for PNH when clinically indicated
  • Age-appropriate evaluation for occult malignancy
  • Selected biomarkers including factor VIII, fibrinogen, D-dimer, lipoprotein(a), and ApoB

Testing is most informative in young patients with recurrent thrombosis, venous thromboembolism, unusual-site thrombosis, pregnancy morbidity, strong family history of thrombosis, unexplained cytopenias, thrombocytosis, erythrocytosis, or laboratory evidence of hemolysis.

The highest diagnostic yield comes not from indiscriminate testing but from a phenotype-driven strategy integrating clinical history, vascular risk factors, and targeted laboratory investigation.”

Heghine Khachatryan: What Should We Test from a Hematology Perspective?

Stay updated on all scientific advances in the field of fertility with Fertility News.

anti-β2 glycoprotein I antibodies anticardiolipin antibodies Antiphospholipid Syndrome antithrombin bilirubin CALR cancer-associated hypercoagulability clonal hematopoiesis Complete blood count Cryptogenic Stroke D-dimer elevated factor VIII erythrocytosis Factor V Leiden factor VIII Fertility Fertility News fibrinogen Heghine Khachatryan hematologic evaluation Hematology Perspective hemolysis-associated thrombosis Homocysteine hyperhomocysteinemia JAK2 V617F laboratory investigation LDH lipoprotein(a) Lupus Anticoagulant myeloproliferative neoplasms ophilia paroxysmal nocturnal hemoglobinuria peripheral blood smear persistent abnormalities platelet disorders Pregnancy Morbidity protein C protein S Prothrombin G20210A Recurrent Thrombosis reproductive health Reproductive Medicine reticulocytes SECRETO study strong family history of thrombosis thrombocytosis unexplained cytopenias unusual-site thrombosis vascular risk factors Venous Thromboembolism
NewsFeed